{
  "docId": "019de074-cfba-73af-96cf-2b33e6c699c9",
  "docSlug": "90ad9e76f71a7983fe14e2a7d36252ee",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 28,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 42,
  "notes": "Data table includes standard error (SE) values for each mean. Footnote provides specific study parameters.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-cfba-73af-96cf-2b33e6c699c9/11",
  "deckHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9",
  "deckJsonHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9.json",
  "deckAnchorHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.38,
        "x": 0.58,
        "y": 0.25
      },
      "kind": "list",
      "text": "All Cohorts achieved at least a -1.8 log10 decline in mean HBsAg at the end of the treatment period (Week 48). Mean HBsAg levels remained below baseline values at Follow Up Week 48. No significant differences between doses or intervals.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f22c2acb-0b1f-40c3-8c10-2e9152081e0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.07,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "Data shown as mean (SE) log10 IU/mL; minimum of 5 subjects/timepoint. Last AB-729 dose Cohort E: Week 44, Cohorts F, I, G, K: Week 40, Cohort J: Week 36; HBsAg Assay LLOQ = 0.07 IU/mL; *N=6; #N=5",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9f11661-53b3-450c-91d1-810fdb7a4a5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.07,
        "y": 0.235
      },
      "kind": "table",
      "text": "Mean (SE) Baseline and Δ log10 HBsAg by Visit",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8785e990-eadb-45d2-84ad-a431accffd25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Robust HBsAg Declines Irrespective of Dose, Dosing Schedule, HBeAg or HBV DNA Status",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27fe87b3-d948-4e04-8ae8-9b00c5dc5d93",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "b84c22bb-2005-4ac9-897d-2d21736cb037",
      "evidence": "table/data: Mean (SE) Baseline and Δ log10 HBsAg by Visit",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 3,
      "beatId": "708d5cbd-cd14-4361-ab43-54fc6ba4b110",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Our Strategy, Broad Pipeline, AB-729 RNAi Therapeutic, and other solution-focused slides",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 16,
      "from": 10,
      "beatId": "506215b6-f901-48ef-83fa-7b3694884e17",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "AB-729-001 Phase 1a/1b Clinical Trial, Robust HBsAg declines, and AB-729-001 Clinical Trial Key Takeaways",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "94df7ae2-9303-427c-ba30-b5689743bab5",
      "evidence": "The document highlights the significant unmet medical need and the limitations of current treatment options.",
      "position": 1,
      "objective": "What are the consequences of not addressing HBV treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}